Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Donna H. Ryan, Ildiko Lingvay, John Deanfield, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 2049-2057
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Jens J. Holst
Nature Metabolism (2024) Vol. 6, Iss. 10, pp. 1866-1885
Open Access | Times Cited: 19
Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1-RAs
Nikolaos Theodorakis, Maria Nikolaou
Biomedicines (2025) Vol. 13, Iss. 1, pp. 135-135
Open Access | Times Cited: 6
Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes
Janet K. Snell‐Bergeon, Gurleen Kaur, D. Renner, et al.
Diabetes Technology & Therapeutics (2025) Vol. 27, Iss. 1, pp. 1-9
Closed Access | Times Cited: 4
How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
Ralf Weiskirchen, Amedeo Lonardo
British Journal of Pharmacology (2025)
Open Access | Times Cited: 3
GLP-1 and the Neurobiology of Eating Control: Recent Advances
Lauren A. Jones, Daniel I. Brierley
Endocrinology (2025)
Open Access | Times Cited: 2
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation
Konstantinos Stefanakis, Michail Kokkorakis, Christos S. Mantzoros
Metabolism (2024), pp. 156057-156057
Closed Access | Times Cited: 11
Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs
Richard Le, Mau T. Nguyen, Momina A. Allahwala, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 16, pp. 4674-4674
Open Access | Times Cited: 10
Emerging Pharmacotherapies for Obesity: A Systematic Review
Michail Kokkorakis, Marlene Chakhtoura, Caline Rhayem, et al.
Pharmacological Reviews (2024) Vol. 77, Iss. 1, pp. 100002-100002
Open Access | Times Cited: 9
Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges
Francisco Westermeier, Enrique Z. Fisman
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial
Robert F. Kushner, Donna H. Ryan, John Deanfield, et al.
Obesity (2025)
Open Access | Times Cited: 1
The potential role of GLP‐1 receptor agonists in osteoarthritis
M P Ryan, Saige Megyeri, Wesley Nuffer, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2025)
Closed Access | Times Cited: 1
Impact of bodyweight loss on type 2 diabetes remission: a systematic review and meta-regression analysis of randomised controlled trials
Sarah Kanbour, Rwedah A. Ageeb, Rayaz A. Malik, et al.
The Lancet Diabetes & Endocrinology (2025)
Closed Access | Times Cited: 1
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT)
Subodh Verma, Helen M. Colhoun, Dror Dicker, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 17, pp. 1678-1682
Open Access | Times Cited: 7
GLP-1 receptor agonism in cardiovascular disease prevention
Hanan Alaaeldin Saleh
Asia-Pacific Journal of Pharmacotherapy & Toxicology (2025)
Closed Access
Thérapeutiques de l’obésité et maladies cardiovasculaires
Pierre Bel Lassen, Judith Aron‐Wisnewsky
Archives des Maladies du Coeur et des Vaisseaux - Pratique (2025)
Closed Access
Clinical considerations in the management of obesity in children and adolescents
Whitney Herring, Carina Kugelmas, Evan P. Nadler, et al.
Obesity Pillars (2025) Vol. 13, pp. 100160-100160
Open Access
Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes
Phil McEwan, Martin Bøg, Mads Faurby, et al.
Journal of Medical Economics (2025), pp. 1-16
Open Access
Social, cultural and ethnic determinants of obesity: from pathogenesis to treatment
Danila Capoccia, Ilaria Milani, Luca Colangeli, et al.
Nutrition Metabolism and Cardiovascular Diseases (2025), pp. 103901-103901
Open Access
Cardioprotective effects of a ‘twincretin’ drug tirzepatide in heart failure following myocardial infarction
Rui Shang, Brian Rodrigues
Cardiovascular Research (2025)
Closed Access
Adipositastherapie und Diabetesprävention mit Tirzepatid
Robin Schürfeld
Deleted Journal (2025)
Closed Access
GLP-1RA: New Hope in Obesity Therapy
Danfeng Zhang, Hongyun Lu
Journal of Biosciences and Medicines (2025) Vol. 13, Iss. 02, pp. 465-479
Open Access
Human Sports Drug Testing: Analytical Challenges and Solutions
Mario Thevis, Katja Walpurgis, Andreas Thomas
Analytical Chemistry (2025)
Closed Access
Semaglutide vs Revisional Bariatric Surgery: What Is the Best Option for Suboptimal Clinical Response or Recurrent Weight Gain After MBS?
Yeisson Rivero-Moreno, Arturo Estrada, Nawaf Hindosh, et al.
Research Square (Research Square) (2025)
Closed Access
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Richard Salvador, Carla Moutinho, Carla Silva, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 399-399
Open Access
An overview of obesity‐related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes
Matthias Blüher
Diabetes Obesity and Metabolism (2025)
Open Access
Page 1 - Next Page

Scroll to top